Disease modification arrives — and the system starts counting the cost
Teplizumab reaches newly-diagnosed children, the GLP-1 bill comes due, and the science narrows on whom to treat.
Six source-worlds — literature, trials, industry, consulting, policy, commentary — in one read.
For a century, treating diabetes has meant controlling its downstream signal — glucose. That is lifesaving, but it has never, on its own, stopped the disease underneath from progressing. This month, for the first time, a therapy reaches the process itself — and the system immediately begins counting what that costs.
The month's highlights, by source-world — each item graded by where its evidence comes from.
Our readThe basic science widened the aperture well beyond glucose this month — population-scale metabolic genetics, the brain circuits that set appetite, and diet–hormone axes (GLP-1, FGF21) tied to healthspan. The throughline: diabetes is increasingly read as a whole-system problem, with the incretins acting on circuitry the field is only now mapping.
Peer-reviewedGenetic analysis of circulating metabolic traits in 619,372 individuals
Population-scale metabolic genetics — the substrate for figuring out who is at risk and why, far upstream of glucose.
Peer-reviewedGlycogen drives the sensory activation of POMC neurons
The brain circuitry of appetite and energy balance — the wiring the incretins ultimately act on.
Peer-reviewedA methionine-supplemented longevity diet raises GLP-1 and FGF21 and promotes healthspan
Diet–hormone axes (GLP-1, FGF21) tied to frailty and healthspan — metabolism read as aging, not just sugar.
PreprintDish-to-biobank: β-cell nutrient-stress programs linked to T2D genetic and dietary risk
A methods bridge from a controlled β-cell model to population genetics; read the methods before the headline.
Our readThis was an ADA Scientific Sessions month, and the incretin field kept escalating: an oral GLP-1 pill (orforglipron) and a triple agonist (retatrutide) pushed weight loss toward bariatric-surgery range, while teplizumab opened a different front — modifying the disease rather than the weight. Across all of it, the unsettled questions are durability and who pays.
TrialATTAIN-2: orforglipron, an oral small-molecule GLP-1, in type 2 diabetes & obesity
The first oral non-peptide GLP-1 in phase 3 — about −9.6% body weight at 72 weeks. A pill changes the access math an injection can't.
TrialRetatrutide (triple agonist): ~45% on the top dose lost ≥30% of body weight
GLP-1/GIP/glucagon agonism reaching a weight-loss threshold once reserved for surgery — the escalation continues.
TrialPROTECT: teplizumab preserves β-cell function in newly-diagnosed children
Primary endpoint met (C-peptide); clinical secondary endpoints did not move — the nuance behind the 2026 approval.
TrialNative GIP, alone or added to semaglutide, did not improve glycemia
A clean negative: 6 weeks of GIP infusion moved nothing — a caution flag on the "more agonism is always better" story.
Our readOne story dominates: the GLP-1 economy, where efficacy is settled enough that access and price are the battleground. A PBM's formulary shift and a multi-billion-dollar oral-biologics deal moved more this month than any trial readout.
Trade pressCVS Caremark drops Novo's preferred edge — adds Lilly's Foundayo pill and Zepbound
Formulary access is the battleground now that efficacy is settled; a PBM's preferred list moves more volume than a trial.
Trade pressNovo Nordisk's deal worth up to $2.1B with Vivtex for oral metabolic biologics
The majors are buying their way beyond injectable GLP-1 — oral biologics look like the next front.
Trade pressU.S. health spending rose ~7.3% toward $6 trillion in 2025, GLP-1s a named driver
The macro-cost line that sits behind every coverage decision.
Our readThe strategy houses have converged on one fork — treat obesity reactively, or get ahead of it through prevention and metabolic health. The open question is which payers and systems actually fund the second path. (Cited, never presented as ours.)
ConsultingGLP-1s are changing obesity care. What comes next? — McKinsey
The market frame: ~900M adults with obesity; scripts +38%/yr; sales toward ~$100B by 2030.
ConsultingThe path toward a metabolic health revolution — McKinsey Health Institute
Two roads: treat obesity reactively, or get ahead of it via prevention and metabolic health.
Our readTwo authorities moved this month, in opposite directions. The FDA widened access (teplizumab, OTC monitoring) while tightening it (the 503B exclusion); the ADA rewrote the playbook — its 2026 Standards made automated insulin delivery the preferred way to dose insulin and, for the first time, backed GLP-1s in type 1 diabetes. The rules of diabetes care are being redrawn as fast as the drugs.
The field's playbook moved — AID gets the strongest recommendation (now for T2D too), CGM expands, and GLP-1s enter T1D guidance for the first time.
GuidelinePediatric Endocrine Society: considerations for using teplizumab in practice
Clinicians translating approval into practice — who to treat, when, and how to weigh burden and infection risk.
GuidelineIDF Diabetes Atlas: 1 in 9 adults now live with diabetes; ~853M projected by 2050
The denominator behind everything above — and a reminder that the access fight looks very different outside the US.
RegulatoryFDA approves teplizumab for recently-diagnosed Stage 3 pediatric T1D
Disease modification reaches newly-diagnosed children — accelerated on a C-peptide surrogate.
RegulatoryFDA clears first OTC continuous glucose monitor for children
Monitoring keeps moving toward consumer access, now for kids.
RegulatoryFDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
The compounded-GLP-1 era begins to close, pulled by a supply lever rather than a clinical one.
Our readThe field's response splits along a familiar line — clinicians on how teplizumab is landing in practice, patient advocates on who can actually get it. Both land on the same gap: early reports put uptake among eligible patients at roughly a third.
Trade pressOnly ~36% of eligible patients started teplizumab — cost, logistics, and treatment burden cited
The patient-side reality check: a first-in-class therapy means little if only a third of eligible families take it on.
Trade pressTeplizumab approved for pediatric Stage 3 T1D — what clinicians are saying
The field's read in real time: enthusiasm tempered by the surrogate-endpoint and durability caveats.
adults projected to be living with diabetes by 2050 — about 1 in 8.
IDF Diabetes Atlasannual growth in GLP-1 prescriptions, 2022–2024.
McKinseyprojected annual GLP-1 sales by 2030.
McKinseyof treated children kept clinically meaningful β-cell function on teplizumab (PROTECT).
NEJM 2023Radar scans six source-worlds each month — the literature, registered trials, industry and deals, the strategy houses, policy and regulators, and field commentary — then surfaces the items that matter and grades each by where its evidence comes from. Consulting analyses are cited, never presented as ours. This is issue No. 1; the source list grows as the scanner's coverage widens.
Sources
- ConsultingMcKinsey. GLP-1s are changing obesity care. What comes next? mckinsey.com
- Trade pressSTAT. U.S. health spending rose sharply in 2025. statnews.com
- RegulatoryFDA. New indication for Tzield (teplizumab), pediatric Stage 3 T1D, 2026. fda.gov
- ConsultingMcKinsey Health Institute. The path toward a metabolic health revolution. mckinsey.com/mhi
Working a diabetes question that deserves more than a headline?
For confidential scientific, pipeline, or strategic diligence inquiries in metabolic disease, start with a brief scoping conversation.
Request a confidential scoping call
Commentary & blogs
field voices